These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer). Tjokroprawiro A Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268 [TBL] [Abstract][Full Text] [Related]
7. The Unitarian Hypothesis for the aetiology of diabetes mellitus. Morrison EY; Ragoobirsingh D; Peter SA Med Hypotheses; 2006; 67(5):1115-20. PubMed ID: 16806731 [TBL] [Abstract][Full Text] [Related]
8. TNFalpha-induced insulin resistance in adipocytes as a membrane microdomain disorder: involvement of ganglioside GM3. Kabayama K; Sato T; Kitamura F; Uemura S; Kang BW; Igarashi Y; Inokuchi J Glycobiology; 2005 Jan; 15(1):21-9. PubMed ID: 15306563 [TBL] [Abstract][Full Text] [Related]
9. Lipid microdomains and insulin resistance: is there a connection? Ikonen E; Vainio S Sci STKE; 2005 Jan; 2005(268):pe3. PubMed ID: 15671480 [TBL] [Abstract][Full Text] [Related]
10. Physiopathological function of hematoside (GM3 ganglioside). Inokuchi J Proc Jpn Acad Ser B Phys Biol Sci; 2011; 87(4):179-98. PubMed ID: 21558756 [TBL] [Abstract][Full Text] [Related]
12. Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Kabayama K; Sato T; Saito K; Loberto N; Prinetti A; Sonnino S; Kinjo M; Igarashi Y; Inokuchi J Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13678-83. PubMed ID: 17699617 [TBL] [Abstract][Full Text] [Related]
13. Obesity causes a shift in metabolic flow of gangliosides in adipose tissues. Tanabe A; Matsuda M; Fukuhara A; Miyata Y; Komuro R; Shimomura I; Tojo H Biochem Biophys Res Commun; 2009 Feb; 379(2):547-52. PubMed ID: 19116132 [TBL] [Abstract][Full Text] [Related]
14. Biology of GM3 Ganglioside. Inokuchi JI; Inamori KI; Kabayama K; Nagafuku M; Uemura S; Go S; Suzuki A; Ohno I; Kanoh H; Shishido F Prog Mol Biol Transl Sci; 2018; 156():151-195. PubMed ID: 29747813 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of insulin sensitizers in diabetes. Jawa A; Fonseca V Curr Opin Investig Drugs; 2006 Sep; 7(9):806-14. PubMed ID: 17002258 [TBL] [Abstract][Full Text] [Related]
16. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Resmini E; Minuto F; Colao A; Ferone D Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513 [TBL] [Abstract][Full Text] [Related]
17. [Hepatogenic diabetes--the current concepts of its pathophysiology and therapy]. Siegel EG; Gallwitz B; Schmidt WE; Fölsch UR Dtsch Med Wochenschr; 1999 Dec; 124(50):1530-5. PubMed ID: 10633781 [No Abstract] [Full Text] [Related]
18. Overcoming insulin resistance with ciliary neurotrophic factor. Allen TL; Matthews VB; Febbraio MA Handb Exp Pharmacol; 2011; (203):179-99. PubMed ID: 21484573 [TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome: are we at risk? Paudel B Nepal Med Coll J; 2007 Sep; 9(3):204-11. PubMed ID: 18092442 [TBL] [Abstract][Full Text] [Related]
20. The metabolic syndrome and nonalcoholic fatty liver disease. Collantes RS; Ong JP; Younossi ZM Panminerva Med; 2006 Mar; 48(1):41-8. PubMed ID: 16633331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]